# 2014

Alicante, Spain

I-01 Jeroen Elassaiss-SchaapTranslational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475Wednesday 10:20-11:50 |

I-02 Moran ElishmereniImproved sunitinib therapy in non-small cell lung cancer as predicted by a new mixed-effects modelWednesday 10:20-11:50 |

I-03 Yumi YamamotoToward a generic PBPK model to predict drug distribution in human brainWednesday 10:20-11:50 |

I-04 Farkad EzzetDose Response Models for Multiple Endpoints: A Simulation StudyWednesday 10:20-11:50 |

I-05 Floris FauchetImpact of maternal zidovudine infusions at labor on fetus: a population pharmacokinetic study Wednesday 10:20-11:50 |

I-06 Sylvain FouliardCardiac safety monitoring in early oncology trials using optimal design and M&S approachWednesday 10:20-11:50 |

I-07 Tomoko FreshwaterCompetitive landscape model using meta-analysis and simulation-based evaluation for Phase IIb study design of MRL-1 being developed for the treatment of rheumatoid arthritis Wednesday 10:20-11:50 |

I-08 Aline FuchsImpact of medication adherence measurement on antiretroviral drug pharmacokinetics: A retrospective cohort study in HIV patients followed by therapeutic drug monitoring and taking part in a medication-adherence enhancing programWednesday 10:20-11:50 |

I-09 María José García SánchezPBPK analysis of doxorrubicin tissue uptake by Simcyp® simulator: influence of gender related variablesWednesday 10:20-11:50 |

I-10 María García-CremadesPharmacokinetic and Pharmacodynamic analysis of Gemcitabine in pancreatic cancer in mice.Wednesday 10:20-11:50 |

I-11 Marc GastonguayProposal for a Web-Based Open Pharmacometrics Curriculum: Results of a Four-Month Pilot EvaluationWednesday 10:20-11:50 |

I-13 Eva GermovsekMechanistic Modelling of Total Body CD4 T-cell Counts from Paediatric HIV Patients Undergoing Planned Treatment InterruptionWednesday 10:20-11:50 |

I-14 Ekaterina GibianskyPopulation Pharmacokinetics of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL)Wednesday 10:20-11:50 |

I-15 Leonid Gibiansky Numerical Testing of Assumptions for Target-Mediated Drug Disposition (TMDD) Equations: Why Inexact Model Provides Satisfactory Description?Wednesday 10:20-11:50 |

I-16 Sandra GilModeling the Postantifungal Effect of Anidulafungin Against CandidaWednesday 10:20-11:50 |

I-17 Anais GlatardA model-based approach to support NOAEL determination: a simulation case illustrated by a real datasetWednesday 10:20-11:50 |

I-18 Bojana GolubovicPopulation pharmacokinetics of sirolimus in adult kidney transplant patientsWednesday 10:20-11:50 |

I-19 Marta GonzalezIn-silico Biopharmaceutical Systems for Provisional Classification of Oral DrugsWednesday 10:20-11:50 |

I-20 Ignacio Gonzalez-GarciaSimulations of populations with different creatinine clearance range and weight to select the best dose of NV22413Wednesday 10:20-11:50 |

I-21 Mario Gonzalez SalesPopulation pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy volunteers.Wednesday 10:20-11:50 |

I-22 Isabel Gonzalez-AlvarezSemi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acidWednesday 10:20-11:50 |

I-23 Sathej GopalakrishnanAssessing treatment failure under combination therapy in HIV diseaseWednesday 10:20-11:50 |

I-24 Verena GottaPower of PKPD analysis to detect QTc effect in preclinical settingWednesday 10:20-11:50 |

I-25 Abhishek GulatiModeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosisWednesday 10:20-11:50 |

I-26 Serge GuzyEvaluation of Bias and Precision using QRPEM algorithm in Phoenix NLME for discrete data modelsWednesday 10:20-11:50 |

I-27 Chihiro HasegawaModeling & simulation of ONO-5334, a cathepsin K inhibitor, to support dose selection in osteoporosisWednesday 10:20-11:50 |

I-28 Michael HeathmanConcentration-Response Modeling of Adverse Event Data using a Markov Chain ApproachWednesday 10:20-11:50 |

I-29 Stefanie HennigPopulation pharmacokinetics of high dose methotrexate in non-Hodgkin lymphoma patientsWednesday 10:20-11:50 |

I-30 Christoph HetheyTowards a cell-level model to predict bacterial growth under antimicrobial perturbationWednesday 10:20-11:50 |

I-31 Jules HeubergerThe prior subroutine explored: pharmacokinetic modeling of THCWednesday 10:20-11:50 |

I-32 Mistry HiteshVirtual Tumour Clinical: translational modelling of vemurafenib, selumetinib and docetaxel inmetastatic melanomaWednesday 10:20-11:50 |

I-33 Rollo HoareModelling CD4 lymphocyte reconstitution following paediatric haematopoietic stem cell transplantationWednesday 10:20-11:50 |

I-34 Nick HolfordEvaluation of NONMEM and Monolix by Parametric BootstrapWednesday 10:20-11:50 |

I-35 Xiao HuExposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis Wednesday 10:20-11:50 |

I-36 Kimberley JacksonPopulation Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats.Wednesday 10:20-11:50 |

I-37 Bart JacobsModel based optimization of a novel controlled release formulation of capecitabineWednesday 10:20-11:50 |

I-38 Esther JanssenSimulations of vancomycin exposure throughout childhood upon commonly used dosing guidelines: towards a model-based dosing regimenWednesday 10:20-11:50 |

I-39 Petra JauslinComparison of post-prandial glucose control by two GLP-1 receptor agonists (lixisenatide and liraglutide) in type 2 diabetesWednesday 10:20-11:50 |

I-40 Garrit JentschThe BAST Clinical Trial Simulator: A computational framework for quantitative risk assessment. Wednesday 10:20-11:50 |

I-41 Jin JinLongitudinal Safety Modeling and Simulation for Regimen Optimization of Vismodegib in Operable Basal Cell CarcinomaWednesday 10:20-11:50 |

I-42 Niclas JonssonA Population PK Analysis of Nebivolol and Valsartan in Combination TherapyWednesday 10:20-11:50 |

I-43 Marija JovanovicEffect of Valproic Acid Daily Dose on Phenobarbital Clearance - Nonlinear Mixed Effects Modelling ApproachWednesday 10:20-11:50 |

I-44 Rasmus Juul KildemoesHow Repeated Time To Event (RTTE) modelling of opioid requests after surgery may improve future post-operative pain managementWednesday 10:20-11:50 |

I-45 Ana NovakovicSample size calculations in multiple sclerosis using pharmacometrics methodology: comparison of a composite score continuous modeling and Item Response Theory approach Wednesday 10:20-11:50 |

I-46 Kristin KarlssonEstimating a Cox proportional hazard model in NONMEMWednesday 10:20-11:50 |

I-47 Mats KarlssonItem response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophreniaWednesday 10:20-11:50 |

I-48 Takayuki KatsubePopulation PK/PD Modeling of Lusutrombopag, Thrombopoietin Receptor Agonist, in Healthy Volunteers for Exploring PK/PD CovariatesWednesday 10:20-11:50 |

I-49 Irene-Ariadne KechagiaA meta-analysis methodology to estimate population pharmacokinetic parameters from reported non-compartmental values with sparse samplingWednesday 10:20-11:50 |

I-50 Ron KeizerExpected effectiveness of reduced-dose efavirenzWednesday 10:20-11:50 |

I-51 David KhanEvaluation of Mechanism Based PKPD Model for AntibioticsWednesday 10:20-11:50 |

I-52 Yukyung KimMetformin's glucose lowering effect in healthy volunteers receiving an oral glucose tolerance testWednesday 10:20-11:50 |

I-53 Yo Han KimEarly characterization of ticagrelor using modeling and simulation analysis of the in vitro platelet aggregation test and human pharmacokinetic dataWednesday 10:20-11:50 |

I-55 William KnebelElastic Cloud Computing in Pharmacometrics: Usage Data and Strategies for Efficient WorkflowsWednesday 10:20-11:50 |

I-56 Gilbert KochSolving Semi-Delay Differential Equations in NONMEMWednesday 10:20-11:50 |

I-57 Markus KraußHierarchical Bayesian-PBPK modeling for physiological characterization and extrapolation of patient populations from clinical dataWednesday 10:20-11:50 |

I-58 Mads KreilgaardStudy design optimization of a morphine analgesia trial using PKPD modelling and simulationWednesday 10:20-11:50 |

I-59 Ryuji KubotaPopulation Pharmacokinetics of Ospemifene and Evaluation for Exposure IncreaseWednesday 10:20-11:50 |